Loading clinical trials...
Loading clinical trials...
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN (REGISTERED)) INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Conditions
Interventions
Genotropin
somatrogon
Locations
32
United States
Center of Excellence in Diabetes and Endocrinology
Sacramento, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Rocky Mountain Pediatric Endocrinology
Centennial, Colorado, United States
Pediatric Endocrine Associates, PC
Greenwood Village, Colorado, United States
Nemours Children's Health System
Jacksonville, Florida, United States
Nemours Children's Specialty Care
Jacksonville, Florida, United States
Start Date
February 7, 2019
Primary Completion Date
August 28, 2020
Completion Date
August 28, 2020
Last Updated
October 14, 2021
NCT07333521
NCT00227253
NCT01604395
NCT06109935
NCT05796440
NCT05230550
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions